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D. Osella et al. ” Antiproliferative activity of a series of cisplatin-based Pt(IV)-acetylamido/carboxylato 
prodrugs” 
DT-ART-12-2015-004905 
Response to Referees 
 
Referee: 1 
The introduction part needs to be further expanded to facilitate the reading especially for the readers 
outside the field. For example, the current status of biologically active asymmetric Pt(IV) prodrugs needs to 
be mentioned, i.e., why it is important to develop new asymmetric Pt(IV) prodrugs that are biologically 
active.  
In the Introduction the importance of developing new asymmetric Pt(IV) prodrugs has been 
explained in the context of drug targeting and delivery. 
The water solubility of complexes 2a-5a and 2b-5b should be measured and the numbers should be included 
in SI.  
The water solubility have been measured and the data have been included in the ESI. 
For the stability tests by NMR, the original NMR spectra should be included in SI and proper comparisons 
should be made.  
The original NMR spectra have been added in the SI. 
For the reduction tests by HPLC in the presence of ascorbic acid, the original HPLC chromatograms of 
other compounds should also be included to support the conclusions on P6, right column, 2nd paragraph. 
The HPLC chromatograms for the reductions of all the compounds have been added in the ESI. 
 
PROF. DOMENICO OSELLA, FRSC 
DIPARTIMENTO DI SCIENZE E INNOVAZIONE 
TECNOLOGICA 
Viale Teresa Michel 11 – 15121 Alessandria 
Tel. 0131 360266 – Fax 0131 360250 
domenico.osella@uniupo.it 
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It is very interesting to see that the acetylamido complex undergoes reduction to have cisplatin as the major 
product and cis-[Pt(acetylamido-N)Cl(NH3)2] as the by-product. What’s the implication of this process on 
the biological activity of the acetylamido complexes compared with that of carboxylato prodrugs? Will the 
replacement of Cl with acetylamido group decrease the cytotoxicity since the by-product is a 
monofunctional Pt(II) compound? 
The implication of this side process is now amply discussed in the text along with the 
appropriate references.  
The original Ep values should be tabulated in the manuscript.  
The Ep values have been added in the ESI. 
The real numbers for the IC50 values should be included in Fig. 3.  
The IC50 values have been moved from SI to Fig. 3.  
“Accumulation ratio” should be clearly defined in the maintext.  
The accumulation ratio is now clearly defined in the text.  
The advantages of having acetylamido Pt(IV) prodrugs rather than carboxylato ones should be emphasized 
in the conclusion, e.g., their good solubility and stability under light. 
The advantages of the new series of compounds have more emphasized in the conclusions. 
 
 
Referee: 2  
on page 5, line 68, is written: “the X-ray structure of 3b, reported in …Figure 1”. According to Scheme 1 
the compound should be 3a and not 3b. 
The label 3b has been replaced in all cases in which it refers to the crystal structure with 3a in 
the main text and in the supplementary information. 
Figure 1, reported in the same page, clearly shows a H-bond (dashed line) between O1 and N1. This is 
visually wrong and contrasts with what is stated on line 89 of the same page (5): “intramolecular hydrogen 
bond with N2”. 
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The Referee is totally right: the drawing has been corrected. 
The authors suggest that the oxidation takes place via a radical mechanism which can well be, but in this 
case I would expect an effect of light which is not taken into account. 
Unfortunately, we have not investigated in deep the effect of the light in the original reaction: all 
the syntheses, including that of 1a were carried out in vessels wrapped with aluminum foils. 
It appears that the Pt(IV) complexes are intrinsically less cytotoxic than the  Pt(II) counterparts and only for 
the most lipophilic derivatives the increased uptake of the Pt(IV) species can compensate for their intrinsic 
smaller activity. In the abstract is stated that the derivatives with longer chains are more active against 
A2780 ovarian cancer cells than cisplatin. This does not appear to be the case from inspection of Figure 3 
(particularly if one takes into account the intrinsic uncertainty of this type of measurements). 
The Referee is totally right: we put too emphasis in the original sentence in the abstract that has 
been reformulated as: “For those with longer chains and hence greater cell uptake, this 
difference is negated and acetylamido complexes are as active as acetato analogues, both 
exhibiting antiproliferative potency (1/IC50) against A2780 ovarian cancer cells similar to that of 
cisplatin.”  
Moreover, in Figure 3 are reported in the ordinate negative values of IC50, which is just a non sense. 
It has been corrected. 
 
Minor points: 
Page 2, line 57: delete the second “peaks”. 
Page 3, line 79: delete [M+H]+. 
Page 5, lines 77-78: An angle cannot be close to linearity. The sentence can be rearranged in the following 
way: “The arrangement of the axial ligands is very close to linearity (N3-Pt1-O2 angle of 175.6(2)°). 
Page 7, line 84: “2-5 pairs” could be better than “2-5 couples”. 
All this typos have been corrected.  
 
Crystallographic Referee: 3  
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There is 1 Structure in this paper. We examined this file: CCDC-1442209. 
It is mentioned in the text that “All the non-hydrogen atoms in the molecules were refined anisotropically.” 
This is not so - C(5) and C(6) were isotropic. I tried anisotropic refinement on them (see 3b.res attached). it 
yields enormous thermal ellipsoids, but consistent with dynamic disorder of this group. I recommend to 
follow this refinement, and the resulting Checkcif alerts to be ignored. 
Also, the orientations of methyl and amino-groups can be optimised (AFIX 137). 
We have tried the anisotropic refinement, but given the checkcif warning that could alarm non-
crystallographers, we decided to stick to the isotropic version.  
Following the recommendations of Referee 3, we have rerun a final anisotropic refinement in 
which we also allowed the rotation of the methyls and of the amino groups using the AFIX 137 
option. All the data in the text and the supplementary materials have accordingly been updated. 
We wish to thank the Referee for his careful checking and his useful suggestions. 
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Antiproliferative activity of a series of cisplatin-based Pt(IV)-
acetylamido/carboxylato prodrugs 
Mauro Ravera,a Elisabetta Gabano,a Ilaria Zanellato,a Federico Fregonese,a Giorgio Pelosi,b James A. 
Platts,c and Domenico Osella,*a 
Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX 5 
DOI: 10.1039/b000000x 
We report studies of a novel series of Pt(IV) complexes exhibiting an asymmetric combination of 
acetylamido and carboxylato ligands in the axial positions. We demonstrate efficient synthesis of a series 
of analogues, differing in alkyl chain length and hence lipophilicity, from a stable acetylamido/hydroxido 
complex formed by reaction of cisplatin with peroxyacetimidic acid (PAIA). NMR spectroscopy and X-10 
ray crystallography confirm the identity of the resulting complexes, and highlight subtle differences in 
structure and stability of acetylamido complexes compared to equivalent acetato complexes. Reduction of 
acetylamido complexes, whether achieved chemically or electro-chemically, is significantly more 
difficult than of acetate complexes, resulting in lower antiproliferative activity for shorter-chain 
complexes. For those with longer chains and hence greater cell uptake, this difference is negated and 15 
acetylamido complexes are as active as acetato analogues, both exhibiting antiproliferative potency 
(1/IC50) against A2780 ovarian cancer cells similar to that of cisplatin. 
Introduction 
Platinum(IV) complexes have been raised in the last decade as a 
possible alternative to the traditional platinum(II)-based 20 
anticancer drugs because of their potential advantages over the 
latter. Platinum(IV) complexes are quite inert toward ligand 
substitution and therefore avoid off-target reactions that 
deactivate Pt(II) complexes and contribute to their side effects. 
Pt(IV) compounds can reach the tumour site intact, where they 25 
are activated through reaction with endogenous reductants, like 
ascorbate, glutathione or proteins (activation by reduction).1 
Bioreduction of Pt(IV) complexes leads to the corresponding 
cytotoxic square-planar Pt(II) species by releasing usually both 
axial ligands. The equatorial ligands determine the nature and 30 
activity of the final metabolite, whereas the two axial ligands 
provide additional opportunities for the tuning of the lipophilicity 
and the rate of reduction of such Pt(IV) prodrugs.2, 3 Additionally, 
the axial ligands can play an important role in the drug targeting 
and delivery (DTD) strategy.3-6 Pt(IV) derivatives bearing 35 
succinic acid/s in axial position/s are well suited for this purpose, 
since one carboxylic group is axially linked to the Pt core while 
the second is available for further reactions with the designed 
biovector (active DTD) or with the designed nanoparticle 
(passive DTD), through amide or ester bond. Using dihydroxido 40 
Pt(IV) synthons for the esterification reaction with the designed 
with succinic anhydride, disuccinato Pt(IV) complexes are easily 
obtained. They can react with one or two designed biovectors 
often giving mixtures of molecules difficult to be separated, or 
large aggregates of uncontrolled dimensions in the case of 45 
reaction with nanoparticles.7 Thus, monofunctional (asymmetric) 
Pt(IV) derivatives are highly desired for such a purpose.8 
 In an attempt to obtain mono-hydroxido Pt(IV) synthons with a 
chemically inert second axial ligand, the Radziszewski reaction 
has been recently applied to the synthesis of a new class of Pt(IV) 50 
complexes.9 This method is based on the reaction between 
acetonitrile and hydrogen peroxide that forms the reactive 
intermediate peroxyacetimidic acid, PAIA (Scheme 1). PAIA 
provides a hydroxido and an acetylamido ligand, the latter being 
N-coordinated during the Pt(II)→Pt(IV) oxidation step. The 55 
resulting (OC-6-44)-(acetylamido-
N)diamminedichloridohydroxidoplatinum(IV), 1a, is highly 
soluble and very stable in water and represents an interesting 
building block for the further development of Pt(IV) antitumor 
prodrug candidates. For this purpose, the reactivity of complex 1a 60 
towards different anhydrides and/or activated carboxylic acids 
has been studied leading to the synthesis of compounds 2a-5a 
(Scheme 1). The newly synthesized complexes were tested in 
vitro on A2780 ovarian cancer cells. Finally, a series of 
monoacetato Pt(IV) analogues was added to compare the 65 
chemical and biological results (series b, Scheme 2). 
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Scheme 1. Reaction scheme for the synthesis of the acetylamido 
complexes 1a-5a (DCC = dicyclohexycarbodiimide) 
 
Scheme 2. Reaction scheme for the synthesis of the acetato complexes 5 
1b-5b (DCC = dicyclohexycarbodiimide) 
Experimental section 
Materials and methods 
K2[PtCl4] (Johnson Matthey and Co.) and all other chemicals 
(Aldrich) were used without further purification. (SP-4-2)-10 
diamminedichloridoplatinum(II) (i.e., cisplatin, cis-
[PtCl2(NH3)2]),10 (OC-6-33)-
diacetatodiamminedichloridoplatinum(IV), 2b11, and (SP-4-3)-
(acetylamido-N)diamminechloridoplatinum(II) (i.e., cis-
[Pt(acetylamido-N)Cl(NH3)2])12 were synthesized according to 15 
literature procedures. The synthesis of 1a has been recently 
reported by us,9 whereas 1b was synthesized by slight 
modifications of a previously reported procedure.13 Complexes 
1a and 1b were also synthesized using 15NH3 to be used in 
mechanistic studies. All reactions were carried out in aluminum-20 
foil-wrapped vessels. 
 The purity of the compounds was assessed by analytical RP-
HPLC, elemental analysis and determination of Pt content by 
inductively coupled plasma-optical emission spectrometry (ICP-
OES). Elemental analyses were carried out with an EA3000 CHN 25 
Elemental Analyzer (EuroVector, Milano, Italy). Platinum was 
quantified by means of a Spectro Genesis ICP-OES spectrometer 
(Spectro Analytical Instruments, Kleve, Germany) equipped with 
a crossflow nebulizer. In order to quantify the platinum 
concentration the Pt 299.797 nm line was selected. A platinum 30 
standard stock solution of 1000 mg L-1 was diluted in 1.0% v/v 
nitric acid to prepare calibration standards. 
 NMR spectra were measured on a Bruker Advance III NMR 
spectrometer operating at 500 (1H), 125.7 (13C), 107.2 (195Pt), and 
50.7 MHz (15N), respectively. 1H and 13C NMR chemical shifts 35 
were reported in parts per million (ppm) referenced to solvent 
resonances. 195Pt NMR spectra were recorded using a solution of 
K2[PtCl4] in saturated aqueous KCl as the external reference. The 
shift for K2[PtCl4] was adjusted to -1628 ppm from Na2[PtCl6] 
(δ = 0 ppm). 15N NMR spectra were recorded using a solution of 40 
15NH4Cl in 1 M HCl as the external reference. [1H, 15N] HSQC 
spectra (Heteronuclear Single Quantum Correlation) were 
obtained with the standard Bruker sequence hsqcetgpsiz with 0.2 
s acquisition time, 8 scans, 1.3 s relaxation delay, and 128 F1 
points. DEPT-45 (Distortionless Enhancement by Polarization 45 
Transfer) spectra were recorded with 100 scans, 3.5 s relaxation 
delay, 0.5 s acquisition time and 75 Hz for 1J (15N, 1H). 
 RP-HPLC and mass analysis were performed using a Waters 
HPLC-MS instrument equipped with Alliance 2695 separations 
module, 2487 dual lambda absorbance detector. The 50 
chromatographic conditions were: silica-based C18 stationary 
phase (5-µm Phenomenex Phenosphere-NEXT C18 column 
250×4.6 mm ID), mobile phase containing 15 mM HCOOH 
aqueous solution and CH3OH in different ratios depending on the 
complex, flow rate = 0.5 mL min-1 (isocratic elution), UV-visible 55 
detector set at 210 nm. Electrospray ionization mass spectra (ESI-
MS) were obtained setting the source and desolvation 
temperatures to 150 °C and 250 °C, respectively, and using 
nitrogen both as a drying and a nebulizing gas. The cone and the 
capillary voltages were usually 30 V or 20 V and 2.70 kV, 60 
respectively. Quasi-molecular ion peaks [M+H]+ were assigned 
on the basis of the m/z values and of the simulated isotope 
distribution patterns. 
 An Autolab PGSTAT12 electrochemical analyser (Eco 
Chemie, Utrecht, The Netherlands) interfaced to a personal 65 
computer running GPES 4.9 electrochemical software was used 
for the electrochemical measurements. A standard three-electrode 
cell was designed to allow the tip of the reference electrode 
(Ag/AgCl, 3M KCl) to closely approach the working electrode (a 
glassy carbon, GC, disk, diameter 0.1 cm, sealed in epoxy resin). 70 
The GC working electrode was polished with alumina, then 
rinsed with distilled water and dried. This process yielded an 
almost completely reproducible surface for all experiments. All 
measurements were carried out under nitrogen in ethanol 
solutions containing 0.1 M [NBu4][ClO4] as supporting 75 
electrolyte and the metal complexes 0.50 mM. All potentials are 
reported vs. Ag/AgCl, 3 M KCl. Positive-feedback iR 
compensation was applied routinely. 
 Synthesis of complexes 2a-4a. Complex 1a (100 mg, 0.266 
mmol) was suspended in DMF (10 mL) at 50 °C and after 5 min a 80 
10-fold excess of anhydride (2.66 mmol, i.e. 272 mg of acetic 
anhydride, 422 mg of butyric anhydride, or 570 mg of hexanoic 
anhydride) was added. The reaction mixture was stirred at 50 °C 
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until suspension became clear (0.5-4 h). The resulting solution 
was filtered, the solvent removed under reduced pressure and the 
residue triturated with diethyl ether. 
2a. Yield: 111 mg (93%). Elemental analysis: found C, 11.2; H, 
3.4; N, 10.3; Pt, 46.5%. Calc. for C4H13Cl2N3O3Pt C, 11.5; H, 5 
3.1; N, 10.1; Pt, 46.8%. 1H NMR (500 MHz, d6-DMSO) δ:  1.88 
(s, 3H, Pt-O-CO-CH3), 1.93 (s, 3H, Pt-NH-CO-CH3), 5.28 (s, 1H, 
Pt-NH-CO-CH3), 6.48 (m, 6H, NH3) ppm. 13C NMR (125.7 MHz, 
d6-DMSO) δ: 23.9 (Pt-O-CO-CH3), 24.9 (Pt-NH-CO-CH3), 175.5 
(Pt-NH-CO-CH3), 178.3 (Pt-O-CO-CH3) ppm. 195Pt NMR (107.2 10 
MHz, d6-DMSO) δ: 496 ppm. ESI-MS (positive ion mode): 
found 418.3 m/z. Calc. for [C4H14Cl2N3O3Pt]+ 418.0 m/z [M+H]+. 
3a. Yield: 108 mg (91%). Elemental analysis: found C, 16.0; H, 
4.0; N, 9.7; Pt, 44.0%. Calc. for C6H17Cl2N3O3Pt C, 16.2; H, 
3.85; N, 9.4; Pt, 43.8%. 1H NMR (500 MHz, d6-DMSO) δ:  0.88 15 
(t, J = 7.4 Hz, 3H, Pt-O-CO-CH2-CH2-CH3), 1.49 (q, J = 7.4 Hz, 
2H, Pt-O-CO-CH2-CH2-CH3), 1.92 (s, 3H, Pt-NH-CO-CH3), 2.14 
(t, J = 7.4 Hz, 2H, Pt-O-CO-CH2-CH2-CH3), 5.16 (s, 1H, Pt-NH-
CO-CH3), 6.48 (m, 6H, NH3) ppm. 13C NMR (125.7 MHz, d6-
DMSO) δ: 13.8 (Pt-O-CO-CH2-CH2-CH3), 18.9 (Pt-O-CO-CH2-20 
CH2-CH3), 25.1 (Pt-NH-CO-CH3), 38.6 (Pt-O-CO-CH2-CH2-
CH3), 175.5 (Pt-NH-CO-CH3), 180.8 (Pt-O-CO-CH2-CH2-CH3) 
ppm. 195Pt NMR (107.2 MHz, d6-DMSO) δ: 496 ppm. ESI-MS 
(positive ion mode): found 446.3 m/z. Calc. for 
[C6H18Cl2N3O3Pt]+ 446.0 m/z [M+H]+. 25 
4a. Yield: 109 mg (87%). Elemental analysis: found C, 20.0; H, 
4.1; N, 8.6; Pt, 41.0%. Calc. for C8H21Cl2N3O3Pt C, 20.3; H, 4.5; 
N, 8.9; Pt, 41.2%. 1H NMR (500 MHz, d6-DMSO) δ: 0.86 (t, 
J = 6.9 Hz, 3H, Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 1.26 (m, 4H, 
Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 1.47 (m, 2H, Pt-O-CO-CH2-30 
CH2-CH2-CH2-CH3), 1.92 (s, 2H, Pt-NH-CO-CH3), 2.15 (t, 
J = 7.4 Hz, 2H, Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 5.16 (s, 1H, 
Pt-NH-CO-CH3), 6.52 (m, 6H, NH3) ppm. 13C NMR (125.7 MHz, 
d6-DMSO) δ: 13.9 (Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 22.0 (Pt-
O-CO-CH2-CH2-CH2-CH2-CH3), 25.1 (Pt-NH-CO-CH3), 25.2 35 
(Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 31.0 (Pt-O-CO-CH2-CH2-
CH2-CH2-CH3), 36.6 (Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 175.5 
(Pt-NH-CO-CH3), 180.9 (Pt-O-CO-CH2-CH2-CH2-CH2-CH3) 
ppm. 195Pt NMR (107.2 MHz, d6-DMSO) δ: 496 ppm. ESI-MS 
(positive ion mode): found 474.1 m/z. Calc. for 40 
[C8H22Cl2N3O3Pt]+ 474.1 m/z [M+H]+. 
 Synthesis of complex 5a. A solution of n-octanoic acid (258 
mg, 1.8 mmol) and dicyclohexylcarbodiimide (DCC, 371 mg, 1.8 
mmol) in DMF (2 mL) was put in ultrasonic bath for 15 min at 
room temperature. After sonication, the filtered solution was 45 
added dropwise to a suspension of 1a (112 mg, 0.3 mmol) in 2 ml 
of DMF. The reaction mixture was stirred for 24 h at 50 °C. 
Solvent was partially removed under reduced pressure and 20 mL 
of diethyl ether were added to obtain 5a as a pale yellow powder. 
Yield: 87 mg (65%). Elemental analysis: found C, 24.4; H, 4.7; 50 
N, 8.1; Pt, 39.3%. Calc. for C10H25Cl2N3O3Pt C, 24.0; H, 5.0; N, 
8.4; Pt, 39.0%. 1H NMR (500 MHz, d6-DMSO) δ:  0.86 (t, J = 6.5 
Hz, 3H, Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.25 (m, 
8H, Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.46 (m, 2H, 
Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.92 (s, 2H, Pt-55 
NH-CO-CH3), 2.15 (t, J = 7.5 Hz, 2H, Pt-O-CO-CH2-CH2-CH2-
CH2-CH2-CH2-CH3), 5.16 (s, 1H, Pt-NH-CO-CH3), 6.47 (m, 6H, 
NH3) ppm. 13C NMR (125.7 MHz, d6-DMSO) δ: 13.9 (Pt-O-CO-
CH2-CH2-CH2-CH2-CH2-CH2-CH3), 22.1 (Pt-O-CO-CH2-CH2-
CH2-CH2-CH2-CH2-CH3), 25.1 (Pt-NH-CO-CH3), 25.5 (Pt-O-60 
CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 28.6-28.7 (Pt-O-CO-
CH2-CH2-CH2-CH2-CH2-CH2-CH3), 31.2 (Pt-O-CO-CH2-CH2-
CH2-CH2-CH2-CH2-CH3), 36.6 (Pt-O-CO-CH2-CH2-CH2-CH2-
CH2-CH2-CH3), 175.5 (Pt-NH-CO-CH3), 180.9 (Pt-O-CO-CH2-
CH2-CH2-CH2-CH2-CH2-CH3) ppm. 195Pt NMR (107.2 MHz, d6-65 
DMSO) δ: 496 ppm. ESI-MS (positive ion mode): found 502.2 
m/z. Calc. for [C10H26Cl2N3O3Pt]+ 502.1 m/z [M+H]+. 
 Synthesis of complex 1b. Cisplatin (100 mg, 0.33 mmol) was 
suspended in acetic acid (40 mL) and H2O2 50% w/w (1 mL, 35 
mmol) was added. The reaction mixture was stirred at room 70 
temperature until the solution becomes clear (ca. 3 h). The 
solution was filtered, the solvent removed under reduced 
pressure, and the residue triturated with diethyl ether to obtain 1b 
as a pale yellow solid. Yield: 110 mg (88%). Elemental analysis: 
found C, 6.6; H, 3.0; N, 7.2; Pt, 51.6%. Calc. for C2H10Cl2N2O3Pt 75 
C, 6.4; H, 2.7; N, 7.45; Pt, 51.9%. 1H NMR (500 MHz, d6-
DMSO) δ: 1.91 (s, 3H, CH3), 5.93 (t with 195Pt satellites peaks, 
1JH-N = 52.9 Hz, 2JH-Pt = 53.0 Hz, 6H, NH3) ppm. 13C NMR 
(125.7 MHz, d6-DMSO) δ: 23.7 (CH3), 178.4 (Pt-O-CO) ppm. 
195Pt NMR (107.2 MHz, d6-DMSO) δ: 1041 ppm. ESI-MS 80 
(positive ion mode): found 377.3 (47%) and 359.0 (100%) m/z. 
Calc. for [C2H11Cl2N2O3Pt]+ 377.0 [M+H]+ and 
[C2H9Cl2N2O2Pt]+ 359.0 [M-OH]+ m/z. 
 Synthesis of complexes 3b and 4b. Complex 1b (100 mg, 
0.266 mmol) was suspended in DMF (10 mL) at 50 °C and after 5 85 
min a 10-fold excess of anhydride (2.66 mmol, i.e. 422 mg of 
butyric anhydride, or 570 mg of hexanoic anhydride or 266 mg of 
succinic anhydride) was added. The reaction mixture was stirred 
at 50 °C until suspension becomes clear (0.5-4 h). The resulting 
solution was filtered, the solvent removed under reduced pressure 90 
and the residue triturated with diethyl ether. 
3b. Yield: 106 mg (90%). Elemental analysis: found C, 16.4; H, 
3.5; N, 6.5; Pt, 43.4%. Calc. for C6H16Cl2N2O4Pt C, 16.15; H, 
3.6; N, 6.3; Pt, 43.7%. 1H NMR (500 MHz, d6-DMSO) δ:  0.87 (t, 
3H, J = 7.4 Hz, Pt-O-CO-CH2-CH2-CH3), 1.47 (q, 2H, J = 7.4 95 
Hz, Pt-O-CO-CH2-CH2-CH3), 1.90 (s, 3H, Pt-O-CO-CH3), 2.19 
(t, 2H, J = 7.4 Hz, Pt-O-CO-CH2-CH2-CH3), 6.52 (m, 6H, NH3) 
ppm. 13C NMR (125.7 MHz, d6-DMSO) δ: 13.6 (Pt-O-CO-CH2-
CH2-CH3), 18.8 (Pt-O-CO-CH2-CH2-CH3), 22.9 (Pt-O-CO-CH3), 
37.7 (Pt-O-CO-CH2-CH2-CH3), 178.2 (Pt-O-CO-CH3), 180.8 (Pt-100 
O-CO-CH2-CH2-CH3) ppm. 195Pt NMR (107.2 MHz, d6-DMSO) 
δ: 1224 ppm. ESI-MS (positive ion mode): found 447.3 m/z. 
Calc. for [C6H17Cl2N2O4Pt]+ 447.0 m/z [M+H]+. 
4b. Yield: 107 mg (85%). Elemental analysis: found C, 20.0; H, 
4.5; N, 5.9; Pt, 41.3%. Calc. for C8H20Cl2N2O4Pt C, 20.3; H, 105 
4.25; N, 5.9; Pt, 41.1%. 1H NMR (500 MHz, d6-DMSO) δ:  0.86 
(t, J = 7.0 Hz, 3H, Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 1.26 (m, 
4H, Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 1.45 (m, 2H, Pt-O-CO-
CH2-CH2-CH2-CH2-CH3), 1.90 (s, 2H, Pt-O-CO-CH3), 2.20 (t, 
J = 7.4 Hz, 2H, Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 6.52 (m, 6H, 110 
NH3) ppm. 13C NMR (125.7 MHz, d6-DMSO) δ: 13.9 (Pt-O-CO-
CH2-CH2-CH2-CH2-CH3), 21.9 (Pt-O-CO-CH2-CH2-CH2-CH2-
CH3), 22.9 (Pt-O-CO-CH3), 25.1 (Pt-O-CO-CH2-CH2-CH2-CH2-
CH3), 30.8 (Pt-O-CO-CH2-CH2-CH2-CH2-CH3), 35.6 (Pt-O-CO-
CH2-CH2-CH2-CH2-CH3), 178.2 (Pt-O-CO-CH3), 180.9 (Pt-O-115 
CO-CH2-CH2-CH2-CH2-CH3) ppm. 195Pt NMR (107.2 MHz, d6-
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DMSO) δ: 1223 ppm. ESI-MS (positive ion mode): found 475.1 
m/z. Calc. for [C8H21Cl2N2O4Pt]+ 475.0 m/z [M+H]+. 
 Synthesis of complex 5b. A solution of n-octanoic acid (258 
mg, 1.8 mmol) and DCC (371 mg, 1.8 mmol) in DMF (2 mL) 
was put in ultrasonic bath for 15 min at room temperature. After 5 
sonication, the filtered solution was added dropwise to a 
suspension of 1b (113 mg, 0.3 mmol) in 2 ml of DMF. The 
reaction mixture was stirred for 24 h at 50 °C. Solvent was 
partially removed under reduced pressure and 20 mL of diethyl 
ether were added to obtain 5b as a pale yellow powder. Yield: 82 10 
mg (61%). Elemental analysis: found C, 24.1; H, 5.3; N, 5.5; Pt, 
38.9%. Calc. for C10H24Cl2N2O4Pt C, 23.9; H, 4.8; N, 5.6; Pt, 
38.8%. 1H NMR (500 MHz, d6-DMSO) δ:  0.86 (t, J = 6.8 Hz, 
3H, Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.25 (m, 8H, 
Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.45 (m, 2H, Pt-O-15 
CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 1.90 (s, 2H, Pt-O-CO-
CH3), 2.20 (t, J = 7.4 Hz, 2H, Pt-O-CO-CH2-CH2-CH2-CH2-CH2-
CH2-CH3), 6.47 (m, 6H, NH3) ppm. 13C NMR (125.7 MHz, d6-
DMSO) δ: 14.4 (Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 
22.6 (Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 23.4 (Pt-O-20 
CO-CH3), 24.9 (Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 
25.8 (Pt-O-CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 29.0 (Pt-O-
CO-CH2-CH2-CH2-CH2-CH2-CH2-CH3), 31.7 (Pt-O-CO-CH2-
CH2-CH2-CH2-CH2-CH2-CH3), 36.2 (Pt-O-CO-CH2-CH2-CH2-
CH2-CH2-CH2-CH3), 178.7 (Pt-O-CO-CH3), 181.4 (Pt-O-CO-25 
CH2-CH2-CH2-CH2-CH2-CH2-CH3) ppm. 195Pt NMR (107.2 
MHz, d6-DMSO) δ: 1223 ppm. ESI-MS (positive ion mode): 
found 503.2 m/z. Calc. for [C10H25Cl2N2O4Pt]+ 503.1 m/z 
[M+H]+. 
 Synthesis of 15NH3-containing complexes 1a and 1b. The 30 
syntheses of complexes 1a and 1b containing 15N ammonia were 
the same of those containing 14NH3,9, 13 but starting from cis-
[PtCl2(15NH3)2].14 The relevant characterization data are reported 
below. 
(15N) 1a. 15N NMR (50.7 MHz, 10% D2O) δ: -39.7 (with satellite 35 
peaks at -37.1 ppm and -42.3 ppm, 1JPt-N = 260 Hz and 2JPt-H = 53 
Hz) ppm. 1H NMR (500 MHz 10% D2O) δ: 2.13 (s, 3H, CH3), 
6.11 (d with 195Pt satellite peaks, 1JH-15N = 75 Hz, 2JH-Pt = 53 Hz, 
6H, NH3) ppm. ESI-MS (positive ion mode): found 378.1 (9%) 
and 360.1 (100%) m/z. Calc. for [C2H12Cl2N15N2O2Pt]+ 378.0 40 
[M+H]+ and [C2H10Cl2N15N2OPt]+ 360.0 [M-OH]+ m/z. 
(15N) 1b. 15N NMR (50.7 MHz, 10% D2O) δ: -35.7 (with 195Pt 
satellite peaks at -33.0 ppm and -38.4 ppm, 1JPt-N = 270 Hz and 
2JPt-H = 53 Hz) ppm; 1H NMR (500 MHz; 10% D2O) δ: 2.13 (s, 
3H, CH3), 6.06 (d with 195Pt satellite peaks, 1JH-15N = 75 Hz, 2JH-Pt 45 
= 53 Hz, 6H, NH3) ppm. ESI-MS (positive ion mode): found 
379.3 (47%) and 361.2 (100%) m/z. Calc. for 
[C2H11Cl215N2O3Pt]+ 379.0 [M+H]+ and [C2H9Cl215N2O2Pt]+ 
361.0 [M-OH]+ m/z. 
X-ray structure of 3b 50 
Crystals of 3b suitable for single-crystal X-ray diffraction were 
grown by slow evaporation of aqueous solution of the complex. 
A specimen of size 0.6×0.4×0.4 mm, was mounted on a glass 
fibre and used for data collection on a SMART APEX2 
diffractometer [λ(Mo-Kα) = 0.71073 Å]. The crystal is 55 
monoclinic, space group P21/c, cell parameters of a = 10.400(2), 
b = 10.093(2), c = 13.361(2) Å, β = 100.644(3)°, V = 1378.4(4) 
Å3. The asymmetric unit is formed by two independent molecules 
of formula C6H17Cl2N3O3Pt, Mr = 445.21, Z = 4, Dc = 2.14 g cm-
3
, µ = 10.56 mm-1, F(000) =840. A semi-empirical absorption 60 
correction, based on multiple scanned equivalent reflections, has 
been carried out and gave 0.3658 < T < 0.7459). A total of 15205 
reflections were collected up to a θ range of 29.31° (±14 h, ±13 k, 
±18 l), 3750 unique reflections (Rint = 0.071). The SAINT 
software15 was used for integration of reflection intensity and 65 
scaling, and SADABS16 for absorption correction. Structures 
were solved by direct methods using SIR9717 and refined by full-
matrix least-squares on all F2 using SHELXL9718 implemented in 
the WinGX package.19 All the non-hydrogen atoms in the 
molecules were refined anisotropically. The hydrogen atoms were 70 
partly found and partly placed in the ideal positions using riding 
models. CCDC 1442209 contains the supplementary 
crystallographic data 
(http://www.ccdc.cam.ac.uk/data_request/cif; see also ESI). 
Theoretical calculations 75 
DFT calculations were performed at the B3LYP level,20, 21 with 
SDD core potential and basis set on Pt22 and 6-31+G(d,p) on light 
atoms,23, 24 using Gaussian09.25 Complexes were built manually 
and geometry optimised without any symmetry constraint, and 
the resulting structures confirmed as true minima through 80 
harmonic frequency calculation. Atomic partial charges were 
calculated using the Natural Bond Orbital (NBO) scheme.26 
Solvation effects were accounted for by the polarizable 
continuum model (PCM) approach.27 
Solution behaviour and reduction reactions 85 
The stability of complexes of the series a and b was studied by 
means of 1H NMR spectroscopy. The complexes ([Pt] = 20 mM, 
except 4a/b and 5a/b where saturated solutions were employed, 
[Pt] < 20 mM) were dissolved in 100 mM phosphate buffer (D2O, 
pH 7.4) and maintained at 25 °C up to 3 d. 90 
 The reduction of complexes of the series a and b (0.5 mM) 
with ascorbic acid (5 mM) was studied in HEPES (2 mM, pH 7.5) 
at 25 °C. All these reactions were followed by monitoring the 
decrease of the area of the chromatographic peaks of the Pt 
complexes in HPLC-UV-MS. The mobile phase was a mixture of 95 
15 mM aqueous HCOOH and CH3OH in a ratio depending on the 
lipophilicity of the complex (from 90/10 to 30/70). 15N NMR 
spectra of 20 mM solutions of Pt complexes and 40 mM ascorbic 
acid were recorded in 80 mM HEPES with 10% v/v D2O at 
25 °C. 100 
Cell culture and viability tests 
The compounds under investigation were tested on the human 
ovarian carcinoma cell line A2780, from ECACC, purchased 
from ICLC (Interlab Cell line Collection, IST Genova, Italy). The 
cells were grown in RPMI-1640 medium supplemented with L-105 
glutamine (2 mM), penicillin (100 IU mL-1), streptomycin (100 
mg L-1) and 10% fetal bovine serum. Cell culture and the 
treatments were carried on at 37 °C in a 5% CO2 humidified 
chamber. Cisplatin was dissolved in 0.9% w/v NaCl aqueous 
solution brought to pH 3 with HCl (final stock concentration 1 110 
mM). All Pt(IV) complexes and [Pt(acetylamido-N)Cl(NH3)2] 
were dissolved in water or absolute ethanol (final stock 
concentration 1-5 mM) and stored at -20 °C. The concentration 
was confirmed by means of ICP-OES. 
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 The mother solutions were diluted in complete medium, to the 
required concentration range. In the case of co-solvent the total 
absolute ethanol concentration never exceeded 0.2% (this 
concentration was found to be non-toxic to the tested cell). Cells 
were treated with the compounds under investigation for 72 h. To 5 
assess the growth inhibition of the compounds under 
investigation, a cell viability test, i.e. the resazurin reduction 
assay, was used.28 Briefly, cells were seeded in black sterile 
tissue-culture treated 96-well plates. At the end of the treatment, 
viability was assayed by 10 µg mL-1 resazurin (Acros Chemicals, 10 
France) in fresh medium for 1 h at 37 °C, and the amount of the 
reduced product, resorufin, was measured by means of 
fluorescence (excitation λ = 535 nm, emission λ = 595 nm) with 
a Tecan Infinite F200Pro plate reader (Tecan, Austria). In each 
experiment, cells were challenged with the drug candidates at 15 
different concentrations and the final data were calculated from at 
least three replicates of the same experiment performed in 
triplicate. The fluorescence of 8 wells containing the medium 
without cells was used as blank. Fluorescence data were 
normalized to 100% cell viability for untreated (NT) cells. Half 20 
inhibiting concentration (IC50), defined as the concentration of 
the drug reducing cell viability by 50%, was obtained from the 
dose-response sigmoid using Origin Pro (version 8, Microcal 
Software, Inc., Northampton, MA, USA). 
Cellular Pt accumulation 25 
A2780 cells were seeded in 25 cm2 T-flasks and treated with the 
complexes under investigations (10 µM) for 4 h. At the end of the 
exposure, cells were washed three times with phosphate buffered 
saline, detached from the Petri dishes using 0.05% Trypsin 1X + 
2% EDTA (HyClone, Thermo Fisher) and harvested in fresh 30 
complete medium. An automatic cell counting device 
(Countess®, Life Technologies), was used to measure the number 
and the mean diameter from every cell count. From the same 
sample, about 5×106 cells were taken out for cellular 
accumulation analysis. Moreover, 100 µL of medium were taken 35 
out from each sample at time zero to check the extracellular Pt 
concentration. For the cellular Pt accumulation analysis, the cells 
were transferred into a borosilicate glass tube and centrifuged at 
1100 rpm for 5 min at room temperature. The supernatant was 
carefully removed by aspiration, while about 200 µL of the 40 
supernatant were left in order to limit the cellular loss. Cellular 
pellets were stored at -20 °C until mineralization. Platinum 
content determination was performed by ICP-MS (Thermo Optek 
X Series 2). Instrumental settings were optimized in order to 
yield maximum sensitivity for platinum. For quantitative 45 
determination, the most abundant isotopes of platinum and 
indium (used as internal standard) were measured at m/z 195 and 
115, respectively. Mineralization was performed by addition of 
70% w/w HNO3 to each sample (after defrosting), followed by 
incubation for 1 h at 60 °C in an ultrasonic bath. Before the ICP-50 
MS measurement, the HNO3 was diluted to a final 1% 
concentration. The cellular Pt accumulation was referred as ng Pt 
per 106 cells. In order to obtain the Pt cellular concentration, the 
total cellular volume of each sample was obtained considering the 
mean cell diameter and cell number estimated by means of an 55 
automatic cell counting device (Countess®, Life Technologies). 
The ratio between the internal and the external cell Pt 
concentration, namely, the Accumulation Ratio (AR) was 
computed as previously reported.29 
Results and Discussion 60 
Synthesis of 1a-5a and 1b-5b and X-ray structure of 3a 
Complex 1a has been synthesized upon oxidation of cisplatin 
with hydrogen peroxide in a mixture of acetonitrile and methanol, 
according to a recently reported method.9 During this reaction the 
reactive intermediate PAIA (Scheme 1) provides a hydroxide and 65 
an acetylamido ligand, the latter being N-coordinated during the 
Pt(II)→Pt(IV) oxidation step. The peroxide PAIA has a quite 
unstable oxygen-oxygen bond,30 which should easily split into 
reactive radicals (namely •OH and •OC(=NH)CH3) via homolytic 
cleavage able to coordinate to Pt during its oxidation from II to 70 
IV redox state. ESR measurements, performed on the reaction 
mixture using 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) as spin 
trap, confirm the formation of radical species. However, the 
presence of several solvents (in particular acetonitrile and 
methanol that can react with H2O2 and change the coupling 75 
constants) makes the interpretation of the spectra doubtful. 
 Interestingly, the final product 1a has the acetylamido 
fragment N-coordinated. The mesomeric transformation from O-
bonded to N-bonded acetylamido is justified considering the 
relative stability of the two possible complexes. In spite of its 80 
high oxidation state, Pt(IV) is classified as a soft ion in the 
Pearson's HSAB theory, and therefore it should prefer N-over O-
coordination.31 Moreover, the ground state energy evaluated for 
both the isomeric complexes by means of DFT calculations give 
free energy difference of 55.8 kJ mol-1 in favour of the N-85 
coordinated over O-coordinated form. 
 Complex 1b was obtained from the oxidation of cisplatin with 
hydrogen peroxide in acetic acid according a slight modification 
of a previously reported procedure (Scheme 2).13 These two 
compounds were reacted with the different anhydrides, to obtain 90 
the axially asymmetric complexes 2a/b-4a/b, or with activated n-
octanoic acid, to obtain 5a and 5b. The reaction of 1a with 
anhydrides/octanoic acid did not modify the arrangement of the 
coordinating atoms around the Pt centre (i.e. the cisplatin 
arrangement), as testified by the NMR data. In fact, all complexes 95 
of the a series show a 195Pt NMR chemical shift similar to that of 
the prototype 1a, in the 400-500 ppm region (for series b 195Pt 
NMR chemical shift falls in the 1000-1250 region). 
 The X-ray structure of 3a, represented in the ORTEP view of 
Fig. 1, confirms the presence of a “N3Cl2O” arrangement around 100 
the Pt atom. The coordination geometry of Pt(IV) is octahedral 
with the equatorial plane occupied by the two chlorido ligands 
[Pt–Cl1 2.325(2) and Pt–Cl2 2.314(2) Å] and the two ammonia 
molecules [Pt–N1 2.052(6) and Pt–N2 2.036(5) Å]. The 
octahedral coordination is completed by the acetylamido ligand, 105 
which occupies one apical position through the deprotonated 
amino group (Pt-N3 1.987(7) Å), and the butanoato, through the 
deprotonated OH group (Pt-O2 2.039(6) Å). The arrangement of 
the axial ligands is very close to linearity (N3-Pt1-O2 175.6(2)°). 
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Fig. 1. ORTEP representation of 3a with ellipsoids at 50% probability 
(intramolecular hydrogen bonds are represented with dashed lines). 
The orientation of the butanoato ligand is mainly due to 
bifurcated hydrogen bond between its carbonyl and both 5 
ammonia molecules. The hydrophobic tail showed a certain 
degree of disorder and had to be constrained in the refinement. In 
complex 1a,9 the carboxylate plane almost bisected the N-Pt-N 
angle (47.83°) forming two hydrogen bonds with both ammines, 
while in this molecule, the acetylamido oxygen is involved in 10 
only one intramolecular hydrogen bond with N2 (the 
corresponding angle is 54.71°). In addition, O1 also forms two 
intermolecular hydrogen bonds with both ammines of an adjacent 
centrosymmetrical complex (Fig. 2). Thanks to these latter bonds, 
the molecules interact pairwise, head-to-tail, forming dimer-like 15 
units. These dimeric units are in turn interconnected with each 
other through another set of hydrogen bonds that involves the 
butanoate oxygen coordinated to the platinum. 
 
Fig. 2. Scheme of intermolecular hydrogen bonds which bring to the 20 
formation of dimer-like units of two centrosymmetrically related 
molecules (i = 1-x, 1-y, 1-z). 
Comparing this molecule with similar ones reported in the 
literature32-34 it is possible to observe a common feature that 
characterises these structures. When the two equatorial ammines 25 
are free to rotate around the Pt-N axis, the oxygen atom of the 
carbonyl moiety belonging to the ligand in one of the two axial 
positions forms a strong bifurcated hydrogen bond with them, 
orienting their hydrogens. On the opposite site of the coordination 
plane, the corresponding carbonyl group cannot find ammine 30 
hydrogens suitably oriented to form analogous hydrogen bonds 
and therefore this second carboxyl group is free to rotate around 
the Pt-O bond and orient itself to form other interactions with 
neighbouring molecules. In systems in which the ammine groups 
are part of a more complex molecule,35 and therefore constrained 35 
to certain orientations, the intramolecular hydrogen bonds cannot 
form and the carboxyl groups are free and involved in single 
intra- and inter-molecular bonds. To complete the network of 
interactions that holds together the crystal, a further hydrogen 
bond is found between O2 and N2 of an adjacent molecule (-x+1, 40 
+y+1/2, -z+1/2) which creates a planar network extending 
parallel to the (100) plane of the unit cell. The hydrophobic tails 
of the butanoato chains are exposed on both sides of the plane. 
The whole structure is then completed by van der Waals 
interactions between the hydrophobic surfaces of these planes 45 
(see Fig. S1, ESI). 
Solution behaviour and reduction reactions 
The complexes of the two series were kept in phosphate buffer 
(100 mM in D2O, pH = 7.4) for 3 d at 37 °C, and the solutions 
were analysed by means of 1H NMR spectroscopy. The results 50 
show that the acetylamido complexes (series a) are stable, both 
when maintained in the dark and exposed to natural daylight 
cycles (Figs. S2-S6, ESI), whereas for series b the exposition to 
light influences the solution behaviour (Figs. S7-S13, ESI). In 
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fact, all compounds 1b-5b are stable in the dark (i.e., no variation 
in the axial acetato 1H NMR peak intensity, taken as diagnostic 
signal), in the time interval considered (3 d). In contrast, the 
methyl signal of 1b and 2b decreases with time when the solution 
is not kept in the dark. After 24 h, the CH3 peaks of the 5 
coordinated acetato ligand decreased by 10 and 20%, for 1b and 
2b, respectively. At the same time, an increase of the free acetato 
signal was observed. 195Pt NMR of the aged solutions did not 
show peaks belonging to Pt(II) derivatives, confirming that 
hydrolysis, rather than reduction, occurred. It is generally 10 
believed that Pt(IV) compounds are quite inert to ligand 
substitution reaction; however, it has been reported that aquation 
reaction may occur to some extent,36 in particular after exposure 
to light or in the presence of residual Pt(II) “impurities” that act 
as catalysts.14 15 
 The complexes under investigation were reacted with ascorbic 
acid (AA) as the simplest model of bio-reductant in order to 
verify the reduction kinetics and, more importantly, to identify 
the produced metabolites. All measurements were performed with 
a 10-fold excess of AA in HEPES buffer, monitoring the decrease 20 
of the area of the Pt(IV) HPLC peak. The hydroxido complexes 
1a and 1b showed significant decrease of the HPLC peak area 
(after 24 h 1a and 1b showed a decrease in peak area of about 
45% and 60%, respectively) (Figs. S14 and S19, ESI). On the 
contrary, for all the remaining complexes 2-5/a-b only a 0-15% 25 
of peak decrease was observed in the same timescale (Figs. S5-
S18 and S20-S23, ESI). This is in agreement with the previous 
observation that OH ligands favour the kinetics of Pt(IV) 
reduction over the carboxylato ligands.37 
 As far as the reduction is concerned, the usual Pt(II) 30 
metabolites deriving from the reductive elimination of the axial 
ligands (i.e., cisplatin and its hydrolysed derivatives) were 
observed in both series.1, 11 Interestingly, the reduction process of 
complexes a is accompanied also by the formation of a low 
quantity of cis-[Pt(acetylamido-N)Cl(NH3)2] (Fig. S24, ESI; ESI-35 
MS shows this complex along with some hydrolyzed species) 
(Scheme 3). 
 
Scheme 3. General reduction scheme of complexes a and b. Hydrolyzed 
products and organic residues were omitted for clarity. 40 
To confirm these observations, reduction with AA was performed 
on 1a and 1b bearing 15N ammonia14 as equatorial ligands and 
followed by 15N NMR (twice excess of AA in HEPES buffer; 
Figs. S25-S26, ESI). After 1 h, the [1H, 15N] HSQC spectra 
showed the presence of the signals of residual 1a (15NH3 δ = -45 
39.7 ppm with satellite peaks at -37.1 ppm e -42.3 ppm, 1JPt-
N = 258 Hz and 2JPt-H = 53 Hz; 1H δ = 6.11 ppm) or 1b (15NH3 
δ = -35.7 ppm with satellite peaks at -33.0 ppm e -38.4 ppm, 1JPt-
N = 270 Hz and 2JPt-H = 53 Hz; 1H δ = 6.06 ppm), together with 
that of cisplatin (15NH3 δ = -66.8 ppm with satellite peaks at -63.5 50 
ppm e -69.9 ppm, 1JPt-N = 327 Hz and 2JPt-H = 69 Hz; 1H δ = 4.10 
ppm). As expected, the signal of cisplatin decreased with time 
and new peaks appeared at δ = -65.0 ppm (1H δ = 4.33 ppm) and 
-88.0 ppm (1H δ = 4.25 ppm), respectively. The latter signal falls 
in the typical region for 15N trans to oxygens, supporting the 55 
formation of hydrolysed cisplatin.38 
 In the case of 1a, another peak was present at 15NH3 δ = -69.0 
ppm (1H δ = 4.33 ppm), in a region common to 15N trans to 
chloridos or nitrogens, compatible with the formation of cis-
[Pt(acetylamido-N)Cl(15NH3)2]. Moreover, over time, some other 60 
peaks appeared in the region for 15N trans to oxygens, indicating 
the formation of various new hydrolysed species. 195Pt NMR on 
the same solution showed signals of cisplatin and its hydrolysed 
derivative, along with another peak at -2338 ppm (Fig. S27, ESI). 
A genuine sample of cis-[Pt(acetylamido-N)Cl(NH3)2]12 showed 65 
almost the same 195Pt chemical shift (δ = -2328 ppm in D2O). 
Therefore, the combination of NMR and MS information 
strengthen the hypothesis of the formation of cis-[Pt(acetylamido-
N)Cl(NH3)2] as by-product of the reduction of Pt(IV)-
acetylamido complexes. 70 
 The scrambling between an equatorial chlorido and an axial 
acetato ligand is not unusual, as clearly showed by Gibson et al. 
following the reduction of a number of Pt(IV) derivatives.1 The 
resulting mixed chlorido/carboxylato Pt(II) metabolite should 
retain the original antiproliferative activity, since Keppler et al. 75 
demonstrated that monodentate carboxylato ligands bounded to 
Pt(II) complexes are able to undergo efficient activation by 
aquation.39 The faster the aquation, the faster the coordination to 
DNA and the higher the activity. On the contrary, the scrambling 
between an equatorial chlorido and the axial acetylamido ligand, 80 
partially occurring during the reduction of 1a, causes a decrease 
in the activity of the resulting Pt(II) metabolite, since the N-
acetylamido ligand cannot undergo easily hydrolysis (see below). 
 The redox properties of the two series of compounds were 
tested by linear sweep voltammetry in ethanol solution. All 85 
complexes showed the usual Pt(IV)-electrochemical behaviour: a 
chemically irreversible 2e-, broad reduction peak was observed 
corresponding to the loss of the two axial ligands and the change 
from octahedral Pt(IV) to square-planar Pt(II) species.40 The 
reduction peak potentials, Ep, of complexes a and b, reveal that 90 
the acetylamido complexes are reduced at a more cathodic 
potential (∆Ep = 0.165 V as average difference between the two a 
and b series; Table S3, ESI). The N-coordinated acetylamido 
provides more electronic density on the Pt centre than the acetato 
counterpart, making the related a series (thermodynamically) less 95 
easily reducible. This is supported by DFT calculations, from 
which the atomic partial charge on Pt, calculated using the 
Natural Bond Orbital (NBO) scheme,26 in acetato complex is 
predicted to be +0.574, compared to that in acetylamido of 
+0.503. This suggests that N-coordination does indeed donate 100 
more electron density to Pt than O. 
 It has been previously reported for cisplatin-, nedaplatin-, 
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picoplatin-, and oxaliplatin-based Pt(IV) complexes that Ep 
values measured in water increase (becomes less negative) as the 
axial chain length increases.33, 41, 42 On the contrary, it has been 
observed that in organic solvent Pt(IV) complexes with different 
axial chains show very similar Ep values, pointing out that the 5 
chain length of the carboxylato ligand has no influence at all on 
the electronic characteristics of the Pt centre, and, hence, on the 
reduction potential.43 In water different solvation effects on the 
species involved in the reduction mechanism do influence the 
final Ep value. The complexes under investigation confirm the 10 
latter observation: Ep values measured in pure ethanol are very 
similar within each series; unfortunately no well-defined 
reduction peaks could be observed in water to corroborate the 
former statement. 
Antiproliferative activity 15 
The acetylamido complexes 2a-5a were tested on ovarian A2780 
tumor cells, together with their acetato counterparts 2b-5b, 
cisplatin, and cis-[Pt(acetylamido-N)Cl(NH3)2] for comparison 
purposes. The results are expressed in terms of IC50 (half-
maximal inhibitory concentration) and are reported in Fig. 3 (see 20 
also Table S3, ESI). 
 
Fig. 3. Half-inhibitory concentration of cisplatin (CDDP), complexes 2a-
5a, and complexes 2b-5b, measured on A2780 ovarian cancer cells 
treated for 72 h with the compounds. 25 
 It has been reported that Pt(IV) complexes enter cells by 
passive diffusion only, and unlike cisplatin no influx/efflux 
mechanism appears to operate.29 For this reason, lipophilicity, 
directly related to the ability of a molecule to passively cross 
cellular membranes, is a key feature to determine the biological 30 
activity of such complexes. Lipophilicity of the complexes under 
investigation was evaluated by means of HPLC, since retention is 
due to partitioning between C18 chains of the stationary phase 
(representing the cellular membrane) and aqueous eluent 
(representing the water inside and outside cells)33, 44 (Table S3, 35 
ESI). The data show that the retention is minimally affected by 
the presence of coordinated axial acetato (series b) instead of 
acetylamido (series a), whereas it depends mainly on the second 
axial ligand. As expected, this similarity is reflected on the 
accumulation ratio (AR) of the 2-5 pairs (Fig. 4, see also Table 40 
S3, ESI). In the literature, uptake and accumulation of Pt are 
sometimes used as synonymous, but actually the AR is the 
quotient between the internal and the external cellular Pt 
concentration. The (internal) cellular Pt concentration is 
measured taking into account the experimentally measured cell 45 
number and average volume of cells, the external Pt 
concentration is that in the culture medium (experimentally 
verified by ICP-MS). 
 On the contrary, the acetato complexes b show better 
antiproliferative activity with respect to acetylamido complexes a 50 
when the companion carboxylato exhibits shorter chains (2b and 
3b vs. 2a and 3a). As the carboxylato ligand chain extends, 
antiproliferative activities became quite similar (4b and 5b vs. 4a 
and 5a) to the acetylamido ones, matching their similar cell 
uptake. The difference between 2b-3b and 2a-3a may be ascribed 55 
to the different kinetics of reduction: the acetato series b is more 
prone to reduction than series a. Moreover, both series produce 
cisplatin as the major metabolite, but series a produces also 
moderate (about 5% in the abiological conditions employed in the 
reduction experiments with AA) amount of cis-[Pt(acetylamido-60 
N)Cl(NH3)2], which is about 50 times less active than cisplatin 
(IC50 = 24.5 µM, measured from a genuine sample). It is well 
known that monofunctional Pt(II)-triamine complexes such as 
[PtCl(NH3)3]+ have lower activity than bifunctional ones, unless 
they have a bulky amine, such as phenanthriplatin.45-48 Thus, the 65 
formation of the [Pt(acetylamido-N)Cl(NH3)2] metabolite is 
detriment for the overall antiproliferative activity. However, the 
higher lipophilicity imparted by long chains (4b-5b and 4a-5a) 
makes the cell uptake so high to mitigate the above differences. 
Finally, inside each series, the usual relationship is observed: 70 
higher lipophilicity corresponds to lower IC50.42 
 
Fig. 4. Accumulation ratio of cisplatin (CDDP), complexes 2a-5a, and 
complexes 2b-5b, measured on A2780 ovarian cancer cells treated for 4 h 
with the compounds. 75 
Conclusions 
A series (a) of cisplatin-based, asymmetric Pt(IV) complexes of 
general formula [Pt(acetylamido-N)(CH3(CH2)nCOO)Cl2(NH3)2] 
(n = 0, 2, 4, 6), bearing an acetylamido axial ligand were 
synthesized and their antiproliferative potential was evaluated. 80 
Their cytotoxic activity was investigated in A2780 ovarian cancer 
cell line showing IC50 values in the low µM range. This 
antiproliferative activity is similar to or somewhat lower than that 
of the corresponding acetato series (b) 
[Pt(acetato)(CH3(CH2)nCOO)Cl2(NH3)2] (n = 0, 2, 4, and 6) 85 
depending on n. 
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 Interestingly, starting from n = 2, IC50 values are similar to that 
of the prototype metallo-drug cisplatin. Compounds of series a 
can be obtained easily and in high yield, exhibit an optimal 
lipophilicity/aqueous solubility balance, and have good stability 
under light, thus they represent an interesting and promising class 5 
of potential antitumor prodrugs. 
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The synthesis and biological properties of Pt(IV) complexes exhibiting an asymmetric combination 
of axial acetylamido and carboxylato ligands are reported. 
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Fig. 1. ORTEP representation of 3a with ellipsoids at 50% probability (intramolecular hydrogen 
bonds are represented with dashed lines). 
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Fig. 2. Scheme of intermolecular hydrogen bonds which bring to the formation of dimer-like units 
of two centrosymmetrically related molecules (i = 1-x, 1-y, 1-z). 
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Fig. 3. Half-inhibitory concentration of cisplatin (CDDP), complexes 2a-5a, and complexes 2b-5b, 
measured on A2780 ovarian cancer cells treated for 72 h with the compounds. 
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Fig. 4. Accumulation ratio of cisplatin (CDDP), complexes 2a-5a, and complexes 2b-5b, measured 
on A2780 ovarian cancer cells treated for 4 h with the compounds. 
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Scheme 1. Reaction scheme for the synthesis of the acetylamido complexes 1a-5a 
(DCC = dicyclohexycarbodiimide) 
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Scheme 2. Reaction scheme for the synthesis of the acetato complexes 1b-5b 
(DCC = dicyclohexycarbodiimide) 
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Scheme 3. General reduction scheme of complexes a and b. Hydrolyzed products and organic 
residues were omitted for clarity. 
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ELECTRONIC SUPPLEMENTARY INFORMATION 
 
Content: 
Table S1. Crystallographic data for complex 3a. 
Table S2. Selected bond distances (Å), angles (°) and hydrogen bonds for complex 3a. 
Figure S1. View of the packing looking down the c axis of the unit cell and lateral view of 
the same image in which the hydrophobic tails protruding from both sides of 
the sheet are apparent. 
Figures S2-S6. 1H NMR spectra of 1a-5a (fresh solutions and aged 3 d). Solvent: phosphate 
buffer 100 mM in D2O. 
Figures S7-S13. 1H NMR spectra of 1b-5b (fresh solutions and aged 3 d). Solvent: phosphate 
buffer 100 mM in D2O. 
Figures S14-S18.  RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 70:30) of the 
reduction of 1a-5a with ascorbic acid (AsA) ([Pt] = 0.5 mM, [AsA] = 5 mM) in 
HEPES buffer (2 mM, pH 7.5).  
Figure S9-S23.  RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 70:30) of the 
reduction of 1b-5b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer 
(2 mM, pH 7.5).  
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Figure S24.  ESI-MS spectrum of [Pt(acetamidato-N)Cl(NH3)2], obtained as trace product of 
the reduction of the a complexes, and ESI-MS simulation for C2H11ClN3OPt as 
[M+H]+. 
Figure S25.  [1H, 15N] HSQC spectrum of the reduction of 1a (20 mM) in the presence of AsA 
(40 mM) in 80 mM HEPES with 10% v/v D2O after 1 h (left) and 4 h (right) 
reaction time, respectively. 
Figure S26.  [1H, 15N] HSQC spectrum of the reduction of 1b (20 mM) in the presence of 
AsA (40 mM) in 80 mM HEPES with 10% v/v D2O after 4 h reaction time. 
Figure S27.  195Pt NMR spectra of reduction of 1a (20 mM) in the presence of AsA (40 mM) 
in 80 mM HEPES with 10% v/v D2O after 6 h (lower spectrum) and 18 h (upper 
spectrum) reaction time. 
Table S3. Miscellaneous experimental chemical and biological data of the complexes 
under investigation. 
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Table S1. Crystallographic data for complex 3a. 
Chemical formula C6H17Cl2N3O3Pt 
Mr 445.21 
Crystal system Monoclinic 
Space group P21/c 
Temperature / K 293 
Wavelength / Å 0.71073  
a / Å 10.400(2) 
b / Å 10.093(2) 
c / Å 13.361(2) 
α / ° 90.00 
β / ° 100.644(3) 
γ / ° 90.00 
V / Å3 1378.4(4) 
Z 4  
Density / Mg m−3  2.145 
Absorption co-efficient / mm−1 1.056 
Absorption correction  Multi-scan  
F(000)  840 
Total no. of reflections 3752 
Reflections, I > 2σ(I) 3024 
Max. 2θ / °  29.31  
Ranges (h, k, l) −14 ≤ h ≤ 13,−13 ≤ k ≤ 13,−18 ≤ l ≤ 18 
Refinement method  Full-matrix least-squares on F2 
Goodness-of-fit on F2 1.042 
R index [I > 2σ(I)] 0.0415 
R index (all data) 0.0543 
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Table S2. Selected bond distances (Å), angles (°) and hydrogen bonds for complex 3a. 
Pt1-N3 1.987(6)  Pt1-N2 2.036(5) 
Pt1-O2 2.039(5)  Pt1-N1 2.052(7) 
Pt1-Cl2 2.314(2)  Pt1-Cl1 2.325(2) 
N3-C1 1.323(8)  O1-C1 1.227(9) 
O2-C3 1.293(10)  C3-O3 1.206(10) 
C3-C4 1.500(11)  C2-C1 1.518(10) 
C4-C5 1.506(11)  C5-C6 1.548(14) 
 
N3-Pt1-N2 92.9(2)  N3-Pt1-O2 175.6(2) 
N2-Pt1-O2 91.2(2)  N3-Pt1-N1 89.8(3) 
N2-Pt1-N1 89.4(2)  O2-Pt1-N1 92.0(3) 
N3-Pt1-Cl2 89.8(2)  N2-Pt1-Cl2 89.22(17) 
O2-Pt1-Cl2 88.53(17)  N1-Pt1-Cl2 178.58(16) 
N3-Pt1-Cl1 86.89(18)  N2-Pt1-Cl1 179.65(16) 
O2-Pt1-Cl1 89.05(16)  N1-Pt1-Cl1 90.30(17) 
Cl2-Pt1-Cl1 91.04(7)  C1-N3-Pt1 127.6(5) 
C3-O2-Pt1 123.5(5)  O3-C3-O2 125.1(8) 
O3-C3-C4 121.7(9)  O2-C3-C4 113.2(9) 
O1-C1-N3 123.7(7)  O1-C1-C2 120.5(7) 
N3-C1-C2 115.8(7)  C3-C4-C5 116.8(10) 
C4-C5-C6 109.3(14)    
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Donor...Acceptor  Donor-H...Acceptor 
N1...O3 (0) 2.856(.013)  N1-H1A...O3 (0) 100.52( 0.54) 
N2...O3 (0) 2.885(.009)  N2-H2A...O3 (0) 131.35( 0.43) 
N2...O1 (0) 2.783(.009)  N2-H2C...O1 (0) 134.69( 0.40) 
N2...O2 (1) 3.008(.007)  N2-H2B...O2 (1) 143.27( 0.37) 
N1...O1 (2) 2.842(.008)  N1-H1B...O1 (2) 162.95( 0.38) 
N2...O1 (2) 2.963(.007)  N2-H2C...O1 (2) 131.10( 0.38) 
 
Equivalent positions: (0) x, y, z 
 (1) -x+1, +y+1/2, -z+1/2 
 (2) -x+1, -y+1, -z+1 
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Figure S1. View of the packing looking down the c axis of the unit cell (above) and lateral view of 
the same image in which the hydrophobic tails protruding from both sides of the sheet are apparent 
(below). 
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Figure S2. 1H NMR spectra of 1a (upper spectrum: fresh solution; lower spectrum: after 3 d). Solvent: 
phosphate buffer (PB) 100 mM in D2O. The same results were obtained either when the samples were 
maintained in the dark or exposed to natural daylight cycles. 
 
 
Figure S3. 1H NMR spectra of 2a (upper spectrum: fresh solution; lower spectrum: after 3 d). Solvent: 
PB 100 mM in D2O. The same results were obtained either when the samples were maintained in the 
dark or exposed to natural daylight cycles. The signals of diethyl ether (at about 1.2 and 3.7 ppm) are 
also present.  
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Figure S4. 1H NMR spectra of 3a (upper spectrum: fresh solution; lower spectrum: after 3 d). Solvent: 
PB 100 mM in D2O. The same results were obtained either when the samples were maintained in the 
dark or exposed to natural daylight cycles. The signals of DMF (at about 3 ppm) are also present. 
 
Figure S5. 1H NMR spectra of 4a (upper spectrum: fresh solution; lower spectrum: after 3 d). Solvent: 
PB 100 mM in D2O. The same results were obtained either when the samples were maintained in the 
dark or exposed to natural daylight cycles. The signals of diethyl ether (at about 1.2 and 3.7 ppm) are 
also present.  
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Figure S6. 1H NMR spectra of 5a (upper spectrum: fresh solution; lower spectrum: after 3 d). Solvent: 
PB 100 mM in D2O. The same results were obtained either when the samples were maintained in the 
dark or exposed to natural daylight cycles. The signals of diethyl ether (at about 1.2 and 3.7 ppm) are 
also present. 
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Figure S7. 1H NMR spectra of 1b maintained in the dark (upper spectrum: fresh solution; lower 
spectrum: after 3 d). ). Solvent: PB 100 mM in D2O. 
 
 
Figure S8. 1H NMR spectra of 1b exposed to natural daylight cycles (upper spectrum: fresh solution; 
lower spectrum: after 3 d). Solvent: PB 100 mM in D2O. 
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Figure S9. NMR spectra of 2b maintained in the dark (upper spectrum: fresh solution; lower 
spectrum: after 3 d). Solvent: PB 100 mM in D2O. 
 
 
Figure S10. 1H NMR spectra of 2b exposed to natural daylight cycles (upper spectrum: fresh 
solution; lower spectrum: after 3 d). Solvent: PB 100 mM in D2O. 
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Figure S11. 1H NMR spectra of 3b (upper spectrum: fresh solution; lower spectrum: after 3 d). 
Solvent: PB 100 mM in D2O. The same results were obtained either when the samples were 
maintained in the dark or exposed to natural daylight cycles.  
 
 
Figure S12. 1H NMR spectra of 4b (upper spectrum: fresh solution; lower spectrum: after 3 d). 
Solvent: PB 100 mM in D2O. The same results were obtained either when the samples were 
maintained in the dark or exposed to natural daylight cycles.  
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Figure S13. 1H NMR spectra of 5b (upper spectrum: fresh solution; lower spectrum: after 3 d). 
Solvent: PB 100 mM in D2O. The same results were obtained either when the samples were 
maintained in the dark or exposed to natural daylight cycles.  
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Figure S14. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 70:30) of the reduction of 
1a with ascorbic acid (AsA) ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The 
peak of 1a (4.1 min) decreases over the time, whereas a new peak at 3.8 min increases (its ESI-MS 
corresponds to [Pt(acetamidato-N)(NH3)2]
+ together with fragmentations of hydrolyzed cisplatin). In 
the region inside the circle, some different peaks overlap (HEPES buffer, cisplatin and 
[Pt(acetamidato-N)Cl(NH3)2]). The presence of this last species is confirmed by the chromatograms 
of the other a complexes, as in the case of 3a (see Fig. S16), where this peak (4.06 min) is not 
overlapped to that of the original Pt(IV) complex. The ESI-MS spectrum of [Pt(acetamidato-
N)Cl(NH3)2] is reported in Fig. S24. 
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Figure S15. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 90:10) of the reduction of 
2a with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 2a 
slightly decreases but overlaps that of AsA. In the region inside the circle, some different peaks 
overlap (HEPES buffer, cisplatin and its hydrolyzed derivatives). 
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Figure S16. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 70:30) of the reduction of 
3a with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak at 4.06 
min, not overlapped to that of the original Pt(IV) complex (9.53 min), is compatible with 
[Pt(acetamidato-N)Cl(NH3)2], as indicated by the corresponding ESI-MS spectrum (Fig. S24). In the 
region inside the circle, HEPES buffer and cisplatin overlap.   
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Figure S17. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 50:50) of the reduction of 
4a with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 4a 
slightly decreases over the time. In the region inside the circle, some different peaks overlap (HEPES 
buffer, cisplatin and its hydrolyzed derivatives).  
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Figure S18. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 30:70) of the reduction of 
5a with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 5a 
slightly decreases over the time. In the region inside the circle, some different peaks overlap (HEPES 
buffer, cisplatin and its hydrolyzed derivatives).  
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Figure S19. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 90:10) of the reduction of 
1b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 1b 
decreases over the time, whereas new peaks increases in the region inside the circle, where some 
different peaks overlap (HEPES buffer, cisplatin and its hydrolyzed species). 
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Figure S20. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 90:10) of the reduction of 
2b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 2b 
undergoes a very little decrease over the time. In the region inside the circle, some different peaks 
overlap (HEPES buffer, cisplatin and its hydrolyzed derivatives). 
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Figure S21. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 70:30) of the reduction of 
3b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 3b 
slightly decreases over the time. In the region inside the circle, some different peaks overlap (HEPES 
buffer, cisplatin and its hydrolyzed derivatives).  
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Figure S22. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 50:50) of the reduction of 
4b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 4b 
slightly decreases over the time. In the region inside the circle, some different peaks overlap (HEPES 
buffer, cisplatin and its hydrolyzed derivatives). 
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Figure S23. RP-HPLC chromatograms (eluent: 15 mM HCOOH/MeOH 30:70) of the reduction of 
5b with AsA ([Pt] = 0.5 mM, [AsA] = 5 mM) in HEPES buffer (2 mM, pH 7.5). The peak of 5b 
slightly decreases over the time. In the region inside the circle, some different peaks overlap (HEPES 
buffer, cisplatin and its hydrolyzed derivatives). 
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Figure S24. A) ESI-MS spectrum of [Pt(acetamidato-N)Cl(NH3)2] obtained as byproduct of the 
reduction of the a complexes (see Figs. S2 and S3). The spectrum shows the peak corresponding to 
[M+H]+ at 324.3 m/z, and its fragmentations [M-Cl+H2O]
+ at 306.2 m/z and [M-Cl+HCOOH]+ at 
334.3 m/z. B) MS simulation for C2H11ClN3OPt as [M+H]
+. 
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Figure S25. [1H, 15N] HSQC spectrum of the reduction of 1a (20 mM) in the presence of AsA (40 
mM) in 80 mM HEPES with 10% v/v D2O and 5 mM [Cl
-] after 1 h (left) and 4 h (right) reaction 
time, respectively.  
 
Figure S26. [1H, 15N] HSQC spectrum of the reduction of 1b (20 mM) in the presence of AsA (40 
mM) in 80 mM HEPES with 10% v/v D2O and 5 mM [Cl
-] after 4 h reaction time.  
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Figure S27. 195Pt NMR spectra of reduction of 1a (20 mM) in the presence of AsA (40 mM) in 80 
mM HEPES with 10% v/v D2O and 5 mM [Cl
-] after 6 h (lower spectrum) and 18 h (upper spectrum) 
reaction time. 
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Table S3. Miscellaneous experimental chemical and biological data of the complexes under 
investigation. 
Compound solubility [mM][a] Ep [V][b] tR [min][c] IC50 [M][d] AR[d] 
cisplatin - - 5.2 0.480.11 1.400.57 
2a 1089 -0.660 5.4 33.14.7 0.770.21 
3a 37.90.1 -0.688 6.8 11.81.9 0.630.15 
4a 9.60.1 -0.681 14.4 0.200.02 4.440.11 
5a 1.80.1 -0.702 56.8 0.040.01 8.470.94 
2b 10510 -0.486 5.5 12.15.2[e] 0.260.13 
3b 27.00.4 -0.512 6.7 2.850.36 0.770.13 
4b 8.10.1 -0.547 14.1 0.310.15 5.080.81 
5b 3.80.2 -0.526 54.4 0.110.05 7.801.69 
 
[a] The water solubility data were determined from saturated solutions of the Pt(IV) 
complexes in milliQ water. After 24 h stirring in the dark at 25 °C, the solid residue was 
filtered off (0.20 µm regenerated cellulose filters) and the Pt content of the solutions was 
determined by means of ICP-OES. 
[b] Reduction peak potentials (Ep) were measured at a glassy carbon working electrode in 
ethanol solutions containing 0.1 M [NBu4][ClO4] as supporting electrolyte. Scan rate = 
0.2 V s-1. All potentials are reported in V vs. Ag/AgCl, 3 M KCl. 
[c] HPLC retention times (tR) were measured on a C18 column, by using a mobile phase 
containing 15 mM aqueous HCOOH and CH3OH in 1:1 ratio. 
[d] Half-inhibitory concentrations (IC50) and accumulation ratios (AR) were measured on 
A2780 ovarian cancer cell lines, after 72 h and 4 h of treatment, respectively. 
[e] data from I. Zanellato, I. Bonarrigo, D. Colangelo, E. Gabano, M. Ravera, M. Alessio 
and D. Osella, J. Inorg. Biochem., 2014, 140, 219-227.  
See Experimental section for more details. 
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